X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (50) 50
humans (40) 40
oncology (39) 39
volasertib (38) 38
cell cycle proteins - antagonists & inhibitors (27) 27
protein-serine-threonine kinases - antagonists & inhibitors (27) 27
proto-oncogene proteins - antagonists & inhibitors (25) 25
bi 6727 (24) 24
apoptosis (22) 22
cancer (22) 22
volasertib bi 6727 (22) 22
phase-i (21) 21
plk1 (20) 20
female (16) 16
kinases (16) 16
cell cycle (15) 15
male (14) 14
polo-like kinase (14) 14
animals (13) 13
polo-like kinase 1 (13) 13
protein kinase inhibitors - pharmacology (13) 13
neoplasms - drug therapy (12) 12
protein kinase inhibitors - therapeutic use (12) 12
tumors (12) 12
acute myeloid-leukemia (11) 11
cell cycle proteins - metabolism (11) 11
cell line, tumor (11) 11
dose-response relationship, drug (11) 11
protein-serine-threonine kinases - metabolism (11) 11
proto-oncogene proteins - metabolism (11) 11
pteridines - pharmacology (11) 11
adult (10) 10
aged (10) 10
apoptosis - drug effects (10) 10
cancer-cells (10) 10
chemotherapy (10) 10
expression (10) 10
middle aged (10) 10
proteins (10) 10
selective inhibitor (10) 10
advanced solid tumors (9) 9
antineoplastic agents - therapeutic use (9) 9
cell biology (9) 9
cell proliferation - drug effects (9) 9
health aspects (9) 9
medical prognosis (9) 9
open-label (9) 9
pharmacology & pharmacy (9) 9
pteridines - administration & dosage (9) 9
small-molecule inhibitor (9) 9
studies (9) 9
antineoplastic agents - pharmacology (8) 8
antitumor-activity (8) 8
article (8) 8
cancer therapies (8) 8
cancer-therapy (8) 8
cell cycle proteins - genetics (8) 8
dna damage (8) 8
leukemia (8) 8
mutation (8) 8
phosphorylation (8) 8
pteridines - pharmacokinetics (8) 8
antineoplastic combined chemotherapy protocols - therapeutic use (7) 7
care and treatment (7) 7
clinical trials (7) 7
clinical trials as topic (7) 7
dose-escalation (7) 7
hematology (7) 7
hematology, oncology and palliative medicine (7) 7
molecular targeted therapy (7) 7
polo (7) 7
polo-like kinases (7) 7
protein-serine-threonine kinases - genetics (7) 7
proto-oncogene proteins - genetics (7) 7
pteridines - adverse effects (7) 7
pteridines - therapeutic use (7) 7
research paper (7) 7
solid tumors (7) 7
analysis (6) 6
antimitotic agents (6) 6
antineoplastic agents - pharmacokinetics (6) 6
cell cycle - drug effects (6) 6
cell cycle checkpoints - drug effects (6) 6
cells (6) 6
inhibitor (6) 6
metastasis (6) 6
neoplasms - pathology (6) 6
patients (6) 6
polo-like kinase inhibitor (6) 6
protein kinase inhibitors - pharmacokinetics (6) 6
research (6) 6
targeted therapy (6) 6
trial (6) 6
advanced solid malignancies (5) 5
antineoplastic agents (5) 5
carcinoma (5) 5
cell culture (5) 5
cell division (5) 5
dna-damage (5) 5
down-regulation (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Cancer Letters, ISSN 0304-3835, 2016, Volume 385, pp. 179 - 187
Abstract The objective of this study was to determine the therapeutic potential of polo-like kinase 1 (Plk1) inhibition in melanoma, in vivo . Employing Vectra... 
Hematology, Oncology and Palliative Medicine | Plk1 | BI 6727 | Volasertib | Melanoma | PROTEIN | PHOSPHORYLATION | PROLIFERATION | SUPPRESSION | P16(INK4A) | P53 | ONCOLOGY | PLK EXPRESSION | PROGNOSTIC-SIGNIFICANCE | PHASE-I | HUMAN CANCER | Skin Neoplasms - drug therapy | Apoptosis - drug effects | Humans | Caspase 3 - metabolism | Melanoma - enzymology | Ki-67 Antigen - metabolism | Molecular Targeted Therapy | Cell Cycle Proteins - antagonists & inhibitors | Dose-Response Relationship, Drug | G2 Phase Cell Cycle Checkpoints - drug effects | Skin Neoplasms - enzymology | Time Factors | Protein-Serine-Threonine Kinases - antagonists & inhibitors | Cyclin-Dependent Kinase Inhibitor p21 - metabolism | Antineoplastic Agents - pharmacology | Protein-Serine-Threonine Kinases - metabolism | Proto-Oncogene Proteins - metabolism | Skin Neoplasms - pathology | Proto-Oncogene Proteins - antagonists & inhibitors | Pteridines - pharmacology | Cell Cycle Proteins - metabolism | Tumor Suppressor Protein p53 - metabolism | Melanoma - secondary | Xenograft Model Antitumor Assays | Animals | Signal Transduction - drug effects | Tumor Burden - drug effects | Mice, Nude | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Cell Line, Tumor | Cell Proliferation - drug effects | Protein Kinase Inhibitors - pharmacology | Mutation | S Phase Cell Cycle Checkpoints - drug effects | Prevention | Polo | Growth | Therapeutics | Metastasis | Tumor proteins | Homeopathy | Materia medica and therapeutics | Cancer
Journal Article
Cancer Letters, ISSN 0304-3835, 11/2018, Volume 436, pp. 1 - 9
The prognosis of small cell lung cancer (SCLC) is poor despite its good initial response to chemotherapy. Polo-like kinase 1 (PLK1) is a crucial mitotic... 
Small cell lung cancer | BI 6727 | DNA damage | PLK1 | AML PATIENTS | PLK1 INHIBITOR | PHASE-II | OPEN-LABEL | OVARIAN-CANCER | ONCOLOGY | POOR-PROGNOSIS | VOLASERTIB | IN-VIVO | 2ND-LINE TREATMENT | CARCINOMA | Immunohistochemistry | Medical colleges | Chemotherapy | Polo | Analysis | DNA | Lung cancer, Small cell | Genetic aspects | Cancer
Journal Article
CANCER, ISSN 0008-543X, 04/2014, Volume 120, Issue 7, pp. 976 - 982
BACKGROUNDPolo-like kinases (Plks) control multiple steps during the cell cycle, and Plk1 is overexpressed in urothelial cancer (UC). Volasertib (BI 6727), a... 
BLADDER-CANCER | DOXORUBICIN | METHOTREXATE | VINBLASTINE | urothelial cancer | CHEMOTHERAPY | phase 2 trial | CISPLATIN | ONCOLOGY | TRANSITIONAL-CELL CARCINOMA | volasertib | POLO-LIKE-KINASE-1 PLK1 | polo-like kinase inhibitor | TRACT TUMORS | III TRIAL
Journal Article
British Journal of Cancer, ISSN 0007-0920, 05/2014, Volume 110, Issue 10, pp. 2434 - 2440
Journal Article
Nature Reviews Cancer, ISSN 1474-175X, 01/2017, Volume 17, Issue 2, pp. 93 - 115
Journal Article
Journal Article
Translational Oncology, ISSN 1936-5233, 2015, Volume 8, Issue 3, pp. 185 - 195
Abstract Polo-like kinases (Plks) are a family of serine-threonine kinases that regulate multiple intracellular processes including DNA replication, mitosis,... 
Oncology | 1 PHOSPHORYLATION | ONCOLOGY | DNA-DAMAGE | MITOTIC CATASTROPHE | TUMOR-SUPPRESSOR | VOLASERTIB BI 6727 | BOX DOMAIN | CELL-CYCLE | PHASE-I | AURORA-A | SMALL-MOLECULE INHIBITOR
Journal Article
Anti-cancer agents in medicinal chemistry, ISSN 1871-5206, 2017, Volume 17, Issue 9, pp. 1278 - 1291
Journal Article
Oncotarget, ISSN 1949-2553, 2017, Volume 8, Issue 45, pp. 78452 - 78465
Volasertib, a selective PLK1 inhibitor, was effective for acute myeloid leukemia (AML) patients in clinical trials. However, its efficacy was limited in... 
AML | Resistance | MDR1 | PLK1 inhibitor | Volasertib | CELLS | POLO-LIKE-KINASE-1 | PLK1 | INDUCTION | POLO-LIKE KINASE | resistance | CANCER-THERAPY | CELL BIOLOGY | TRIAL | SELECTIVE INHIBITOR | BI 6727 | DRUGS | volasertib
Journal Article
Journal Article